Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Springworks Therapeutics Inc.
Headquarters: Stamford, CT, United States of America
Website: http://www.springworkstx.com...
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: Saqib Islam
Number Of Employees: 368
Enterprise Value: $2,378,345,461
PE Ratio: -10.25
Exchange/Ticker 1: NASDAQ:SWTX
Exchange/Ticker 2: N/A
Latest Market Cap: $2,675,960,832
BioCentury | Mar 20, 2025
Data Byte
FDA’s new and supplemental approvals in February
Springworks gets priority review voucher for Gomekli, first NovoLog biosimilar reaches market, and more
BioCentury | Feb 1, 2025
Data Byte
Four PDUFA dates on FDA’s February agenda
Decisions include a MAP2K1/2 inhibitor that could give Springworks a priority review voucher
BioCentury | Jan 5, 2024
Regulation
FDA’s 2023 approvals — a lull in innovation
2023 delivered the second-largest number of FDA new drug approvals ever, yet less innovation in targets, modalities and indications
BioCentury | Dec 7, 2023
Data Byte
FDA approves six NMEs in November
The four cancer therapies among the approvals included the first AKT inhibitor and the first desmoid tumor therapy
BioCentury | Dec 6, 2023
Deals
Dec. 5 Quick Takes: Nearing clinic, Odyssey raises $101M series C
Plus: Genentech PI3K combo meets PFS endpoint in Phase III and more from ImmunoGen, SpringWorks, Eligo, BrainChild, Axcella, Sanofi, Aqemia and IGM
BioCentury | Nov 28, 2023
Data Byte
With SpringWorks approval, FDA on track for third-most NMEs since '85
2023 approvals already exceed all but three years in past four decades
BioCentury | Nov 27, 2023
Product Development
Nov. 27 Quick Takes: BioNTech grows U.K. presence
Plus: FDA approval for SpringWorks, setback for Aldeyra and updates from Sanofi, Regeneron, GSK, Abeona, Roivant, Sosei Heptares, Xenon, Arvinas, Teva
BioCentury | Nov 16, 2023
Deals
Nov. 16 Quick Takes: Q32 takes merger route to NASDAQ via Homology deal
Plus: SpringWorks’ neurofibromatosis program headed for NDA and updates from Astellas, Propella, BMS, Merck, Nature’s Toolbox, Apollomics and Avistone
BioCentury | Oct 31, 2023
Data Byte
Nine PDUFA dates on FDA’s November roster
Decisions include the first vaccine for Chikungunya and three new cancer therapies
BioCentury | Sep 11, 2023
Management Tracks
Sanofi alum Sibold named CEO at Madrigal
Plus: Fenimore to succeed Landry as Regeneron CFO and updates from SpringWorks, SalioGen, Oxular, Solu, Flagship, Oculis
Items per page:
1 - 10 of 42